QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
QQQ   307.84 (+1.40%)
AAPL   153.82 (+1.38%)
MSFT   266.54 (+3.80%)
META   190.84 (+2.57%)
GOOGL   106.56 (+3.56%)
AMZN   100.63 (-1.52%)
TSLA   194.07 (-0.35%)
NVDA   218.58 (+3.65%)
NIO   10.77 (-1.46%)
BABA   104.86 (-0.56%)
AMD   84.82 (+1.36%)
T   19.26 (-1.63%)
F   13.36 (+1.67%)
MU   61.67 (+2.82%)
CGC   2.78 (-5.76%)
GE   81.49 (-1.04%)
DIS   110.96 (+0.99%)
AMC   6.09 (-10.44%)
PFE   43.41 (-0.80%)
PYPL   82.63 (+0.36%)
NFLX   359.99 (-0.41%)
NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$28.45
+0.29 (+1.03%)
(As of 02/7/2023 03:25 PM ET)
Add
Compare
Today's Range
$27.92
$28.86
50-Day Range
$18.89
$29.09
52-Week Range
$13.05
$29.52
Volume
97,044 shs
Average Volume
390,002 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.57

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.7% Upside
$51.57 Price Target
Short Interest
Bearish
5.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.00mentions of Replimune Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$375,450 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($3.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

449th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

70th out of 168 stocks

REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Replimune Breaks Out: Could Rise 30% From Here
Replimune Shares Rally on Pipeline Advances >REPL
Expert Ratings for Replimune Group
Replimune: Recent Developments Strengthen Bull Thesis
Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?
Replimune Group, Inc. (REPL)
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.57
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+81.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-118,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.71 per share

Miscellaneous

Free Float
37,901,000
Market Cap
$1.42 billion
Optionable
Not Optionable
Beta
1.65

Key Executives

  • Philip Astley-Sparke
    Chief Executive Officer & Director
  • Robert CoffinRobert Coffin
    President & Director
  • Colin A. LoveColin A. Love
    Chief Operating Officer
  • Jean M. Franchi
    Chief Financial Officer, Secretary & Treasurer
  • Pamela EspositoPamela Esposito
    Chief Business Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2023?

7 brokerages have issued twelve-month target prices for Replimune Group's shares. Their REPL share price forecasts range from $34.00 to $70.00. On average, they predict the company's share price to reach $51.57 in the next twelve months. This suggests a possible upside of 81.5% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2023?

Replimune Group's stock was trading at $27.20 at the beginning of the year. Since then, REPL shares have increased by 4.5% and is now trading at $28.42.
View the best growth stocks for 2023 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.38%), Frazier Life Sciences Management L.P. (1.87%), TD Asset Management Inc (0.27%), Moody Aldrich Partners LLC (0.18%), Fisher Asset Management LLC (0.14%) and Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $28.42.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.41 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 152 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 2/7/2023 by MarketBeat.com Staff